Clinical Trial Update: Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006 [Phase 2]

View source ↗

Summary

A Phase 2 escalating and cumulative-dose PK/PD and safety study of the investigational drug A006 by Amphastar Pharmaceuticals has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• A006

Snippet

Sponsor: Amphastar Pharmaceuticals, Inc. | Conditions: Asthma, Bronchospasm | Phase 2 | Status: COMPLETED